Board of Directors & Officers

Mr. Monroy brings a wealth of experience and expertise in quality management, strategic leadership, and operational excellence. As the Chief Executive Officer and founder of Ambioxera Pty Ltd, Mr. Monroy exemplifies visionary leadership, spearheading the company's strategic direction while fostering a culture of continuous improvement and customer-centricity. With a Master's degree in Applied Science with an emphasis in Biotechnology and an MBA with a focus on General Management, and more than 10 years of experience in the serum industry, Mr. Monroy possesses a unique blend of technical expertise and business acumen.

Gareth has worked for TCS Biosciences Ltd for over 20 years and has held the position of Sales and Marketing Director since 2006. TCS is a manufacturer and distributor of a wide range of animal and human derived blood and serum products, producing Donor Horse Serum from herds based on their farm in the UK. TCS has been a member of the ISIA for many years and takes active roles in some of the sub committees. In 2017 they confirmed their commitment to quality and ethics by becoming ISIA Traceability Certified.

Ph.D. in Business Administration, Guilherme Esteves is a Board Member of the International Serum Industry Association (ISIA) and holds positions as International Sales Manager at River City Biologicals, River City Brazil, and Animal Technologies, Inc. With 15+ years of experience in planning and management of commercial, administrative, and financial areas of small and medium-sized companies, Esteves has been working for 11+ years as an entrepreneur, focusing on new business development.

Jared Deppe is the Director of Product Management - Sera, Research, and OEM Products within Cytiva's cell culture business (HyClone). He manages commercial and product strategies for HyClone serum and research portfolios with Cytiva. His 20-year career includes various roles in pricing, finance, and product management. For the last 10 years, Jared has been a leader within Cytiva's serum portfolio and the serum industry. Jared has also served in multiple functions within the ISIA including as CFO and as an active member of the traceability committee. Jared holds a Bachelor's degree from Utah State University in Finance and Economics and an MBA from Weber State University.

Jenny has over 30 years' experience in the cell culture industry, both in the UK and worldwide. Jenny is the past owner of Seralab Ltd. and the current owner of Life Science Group Ltd. (LSG). LSG is an independent manufacturing company based in the UK offering contract manufacturing of various human and animal sera, media and buffers for research, cell therapy and other disciplines. Jenny is very active in support of European Regulatory Affairs, Traceability and Standardization within the Association. She recently served 3 years as the Chair of the ISIA Board of Directors.

Mark Koza serves as Business Director for Media & Serum at Corning Life Sciences, where he has spent his two-decade career. He is responsible for strategy and execution of Corning's global serum portfolio, which includes all stages in the supply chain from supply to customer. Over the years at Corning Life Sciences, Mark has held various roles in commercial and business operations, most recently as Global Business Manager for Serum. He is also a member of the ISIA Traceability team and serves as the ISIA board chair-elect. Mark received his bachelor's degree in microbiology from The University of Maine.

Nicole Green has been involved in the animal serum industry for over 20 years and is currently Vice President of Operations and Communication at Central Biomedia, Inc. She has served in many different roles including quality, production, and management. During her tenure she has been responsible for regulatory affairs, quality, business development, and overall company culture. Nicole has been actively involved in the ISIA as leader of the Traceability Team and is now board chair. Nicole holds a BA in Biology from MidAmerica Nazarene University.

Originally from Ukraine, Vlad graduated from the National University of Life and Environmental Sciences of Ukraine with a degree in veterinary medicine with honors. After moving to Australia in 2012 he worked as a beef farm manager prior to joining Moregate Biotech in 2017, working through all levels of the business from Production Manager to General Manager. He is fascinated by the vastness of animal serum applications on a global scale. Vlad's role has grown to manage the operations of Moregate under new owners after the company was acquired by ANZCO foods in 2022. Vlad lives with his wife and two children in Brisbane, Australia.

Courtney Burnam is the Chief Financial Officer of ISIA, bringing over 12 years of experience in accounting and finance. She currently serves as Controller for Animal Technologies, a role she has held since December 2022, where she oversees financial operations and supports strategic initiatives. Courtney is recognized for her strong financial leadership, analytical expertise, and commitment to organizational excellence.

Kathryn Pagani-Lee is the Director of Administration and Board Secretary at the International Serum Industry Association (ISIA). Since joining ISIA in 2021, she has played a pivotal role in managing administrative operations, coordinating board activities, overseeing the successful execution of the ISIA Annual Meeting, and fostering strong member relations. With a deep commitment to ISIA's mission, Kathryn ensures the seamless operation of the association while supporting initiatives that promote traceability, regulatory compliance, and ethical standards within the global serum industry. Based in Ontario, California, Kathryn continues to drive ISIA's efforts to uphold the highest standards in the serum and biological products sector.